It has always been referred to as an SP1 inhibitor with other data suggesting activity against ETS transcription factors and EWS‐FLI1, the oncogenic driver of Ewing sarcoma (Grohar et al, 2011). The gene discussed is SP1; the disease is Ewing sarcoma.